IPSEN
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) announces today its corporate agenda* for 2016:
1 March 2016: | Full year 2015 sales & results | ||
28 April 2016: | First quarter 2016 sales | ||
31 May 2016: | General shareholders’ meeting | ||
6 June 2016: | Payment of 2015 dividend** | ||
28 July 2016: | First half 2016 sales & results | ||
26 October 2016: | First nine months 2016 sales |
* This financial calendar is for indicative purposes only and the Group
could change its publication dates should it deem it necessary
**
Pending approval of the Board of directors (29 February 2016) and of the
General shareholders’ meeting (31 May 2016)
About Ipsen
Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million, representing about 15% of Group sales. The Group has more than 4,500 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20151217006271/en/
Contact:
Media
Didier Véron
Senior Vice-Président, Public
Affairs
and Communication
Tel.: +33 (0)1 58 33 51 16
Fax:
+33 (0)1 58 33 50 58
E-mail: didier.veron@ipsen.com
or
Brigitte
Le Guennec
Corporate External Communication
Tel.: +33 (0)1
58 33 51 17
Fax: +33 (0)1 58 33 50 58
E-mail : brigitte.le.guennec@ipsen.com
or
Financial
Community
Stéphane Durant des Aulnois
Vice-Président
Investor Relations
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58
33 50 63
E-mail: stephane.durant.des.aulnois@ipsen.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NY-DC-ADMINISTRATION28.3.2024 21:15:26 CET | Press release
DC Secretary Announces Annual Determinations Committees Outcome
CA-HTEC/G2-RISK28.3.2024 17:03:32 CET | Press release
Faster Recoveries, Improved Security: HTEC and G2 Risk Solutions Join Forces to Advance Bankruptcy Management
YCVB28.3.2024 16:01:31 CET | Press release
The reopening of the Yokohama Museum of Art adds another innovative and distinctive venue for events in Yokohama
CA-LAMBDATEST28.3.2024 16:01:31 CET | Press release
LambdaTest Launches The Phoenix Project, an Employee Resource Group for Women
YCVB28.3.2024 16:01:31 CET | Press release
Eight new sustainability-themed experiences—exclusive to Yokohama—for convention participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom